CNPV

News

J&J claims the FDA's third national priority voucher approval, advancing a Tecvayli-based regimen for multiple myeloma into the second-line setting.

News

One of the beneficiaries of the FDA's national priority vouchers, Disc Medicine, has had its marketing application turned down by the regulator.

News

The next two discretionary priority vouchers to be awarded by the FDA are reported to be heading for two MSD drug candidates.

News

The FDA has awarded its latest national priority voucher to Johnson & Johnson for a combination regimen based on Tecvayli for multiple myeloma.

News

FDA approves its first 'national priority' drug – a version of the widely used antibiotic Augmentin XR – in double-quick time.

News

Novo Nordisk is using its recently awarded FDA priority voucher on a high-strength version of its obesity drug Wegovy.